Niche vaccine focus Early-stage biotech focused on immune-modulating products like a poison ivy vaccine, presenting opportunities to engage with life sciences channels, contract research organizations, and immune-oncology players seeking allergen-related solutions.

Small team agility Tiny headcount (2-10) suggests high responsiveness but limited internal capacity; ideal for targeted, low-friction partnerships, consulting-based pilots, and outsourced R&D collaborations to accelerate development.

Academic collaboration Active collaboration with universities (e.g., University of Mississippi) indicates receptiveness to joint research, sponsored projects, and grant-funded programs that can lead to co-development and funded studies.

Early-stage funding Funded with approximately $3.1M and reported revenue near zero; potential buyers or partners may seek risk-sharing licenses, milestone-based deals, or grant-backed collaborations to de-risk entry.

Market positioning Operating in a highly specialized biotech segment with modest revenue but notable press exposure; opportunities exist to position as a niche partner for allergen vaccines, toxin research, and bioscience innovation hubs.